RE:Paroxetine with anti-competitive conduct.....Discussed the article with Billy Kenber yesterday and sent him the Paroxetine article to compare.....
in summary if guilt is found.....
Contains Parliamentary information licensed under the
Open Parliament Licence v3.0. The CMA has found that GSK’s agreements with each of GUK and Alpharma infringed
the competition law prohibition on anti-competitive agreements. The CMA has also found
that GSK’s conduct, in making payments to GUK, Alpharma and one further company,
Norton Healthcare Limited (IVAX), to induce them to delay their efforts to enter the UK
paroxetine market independently of GSK, infringed the competition law prohibition on
abuse of a dominant position. The total fines imposed are as follows: - The total penalty for GSK is £37,606,275 for which each entity comprising GSK (as listed in note 7) is jointly and severally liable.
- The total penalty in respect of GUK is £5,841,286 for which Merck KGaA is liable for £5,841,286; and of that amount Generics (UK) Limited is jointly and severally liable, with Merck KGaA, for £2,732,765.
- The total penalty in respect of Alpharma is £1,542,860 for which each of Actavis UK Limited, Xellia Pharmaceuticals ApS and Alpharma LLC is jointly and severally liable.
Replace GSK with Actavis, GUK with Cinven and Alpharma with Concordia and that is the results if found guilty.